fashion -WSS

fashion

author：focus 2025-09-28 12:10:22 - browse：38919

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Sudafed saga points to U.S. issues with evaluating older drugs

WSS

Timeline: Special counsel's probe into Trump's handling of classified documents

Data show record exodus of life scientists from academia

Ending health disparities requires full federal government, panel says

Ionis has late

Data show record exodus of life scientists from academia

STAT Virtual Event: How to Increase Diversity in Clinical Trials

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

In Memoriam: Notable people who died in 2023

Sudafed saga points to U.S. issues with evaluating older drugs

Bright Health sells Medicare Advantage business to Molina

As the dark side of IVF slowly comes into focus, even more transparency is needed

The cancer drug shortage isn’t new — and neither are the solutions

Mindstrong's demise and the future of mental health care

Trump demands the U.S. pay no more for drugs than other countries … again

Hospitals, health systems can help patients avoid medical debt

Apple is now the first public company to be valued at $3 trillion

FDA advisers vote against ALS treatment from BrainStorm

hotspot

How the Dana

Shingles, which affected Dianne Feinstein, is on the rise

Stoke drug shows lower activity against childhood epilepsy

Biden announces an advanced cancer research initiative

After a drawn out lobbying fight, ARPA

Senator probes 340B programs at Cleveland Clinic, Bon Secours

leisure time

leisure time

explore

leisure time